Shaolin Capital Management’s TriSalus Life Sciences TLSI Stock Holding History

Shaolin Capital Management’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-206,988	Closed	-$2.04M	–	952
2022 Q2	$2.04M	Buy	+206,988	New	+$2.03M	0.05%	398
2021 Q3	–	Sell	-250,000	Closed	-$2.42M	–	576
2021 Q2	$2.42M	Hold	250,000	–	–	0.07%	265
2021 Q1	$2.42M	Buy	+250,000	New	+$2.54M	0.1%	203

Other funds holding TLSI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Shaolin Capital Management's TLSI Position: Q3 2022 in Review

Shaolin Capital Management sold out of TriSalus Life Sciences (TLSI) in Q3 2022, closing a stake of 206,988 shares — an estimated $2.04M sold.

Shaolin Capital Management first reported a position in TLSI in Q1 2021 and held it in 3 quarters. The position peaked at $2.42M in Q2 2021. 72 funds tracked by Wall St. Rank hold TLSI as of Q3 2022.

Shaolin Capital Management reported no remaining TriSalus Life Sciences position as of Q3 2022 after selling out during the quarter.
Shaolin Capital Management sold 206,988 TriSalus Life Sciences shares in Q3 2022, an estimated $2.04M.
Shaolin Capital Management first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 3 quarters.
Shaolin Capital Management's TriSalus Life Sciences position peaked at $2.42M in Q2 2021.
72 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2022.

Based on Shaolin Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.